



US009636363B2

(12) **United States Patent**
Habi et al.

(10) **Patent No.:** **US 9,636,363 B2**

(45) **Date of Patent:** ***May 2, 2017**

(54) **HALOGENATED RHODAMINE
DERIVATIVES AND APPLICATIONS
THEREOF**

(71) Applicant: **KIADIS PHARMA CANADA INC.,**
Saint Laurent (CA)

(72) Inventors: **Abdelkrim Habi**, Pierrefonds (CA);
Denis Gravel, Saint-Lambert (CA);
Luc Villeneuve, Montreal (CA);
Hongsheng Su, Beaconsfield (CA);
Marc Vaillancourt, Chateaugay (CA)

(73) Assignee: **Kiadis Pharma Canada Inc.**, Saint
Lambert, QC (CA)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

This patent is subject to a terminal dis-
claimer.

(21) Appl. No.: **13/752,204**

(22) Filed: **Jan. 28, 2013**

(65) **Prior Publication Data**

US 2014/0314720 A1 Oct. 23, 2014

Related U.S. Application Data

(60) Continuation of application No. 13/157,105, filed on
Jun. 9, 2011, now Pat. No. 8,383,672, which is a
(Continued)

(30) **Foreign Application Priority Data**

Apr. 2, 2001 (CA) 2342675

(51) **Int. Cl.**

A61K 35/28 (2015.01)

C07D 311/82 (2006.01)

A61K 35/14 (2015.01)

(52) **U.S. Cl.**

CPC **A61K 35/28** (2013.01); **A61K 35/14**
(2013.01); **C07D 311/82** (2013.01)

(58) **Field of Classification Search**

CPC **A61K 35/28**
(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,360,734 A * 11/1994 Chapman et al. 435/238

5,556,992 A * 9/1996 Gaboury et al. 549/227

(Continued)

FOREIGN PATENT DOCUMENTS

WO WO 00/17650 * 3/2000 549/227

OTHER PUBLICATIONS

Abrahart Dyes and their Intermediates pp. 225-227.*

(Continued)

Primary Examiner — Taofiq A Solola


(74) *Attorney, Agent, or Firm* — O'Melveny & Myers
LLP

(57)

ABSTRACT

Methods for treating an infection in a tissue sample are described. Tissue samples that are harvested from a patient may be infected with either bacteria or a virus. A rhodamine compound is mixed with the infected tissue sample to form a mixture. The mixture is then exposed to radiant energy to inhibit or kill the bacteria. The exposed mixture is then transplanted into the patient. The rhodamine compounds may be 2'-(6-dimethylamino-3-dimethylimino-3H-xanthen-9-yl) 4', 5'-dichloro-benzoic acid methyl ester hydrochloride.

9 Claims, 18 Drawing Sheets



General synthesis of substituted 4 and 2,7 halogenated rhodamine derivatives